S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Gold Really Boring? (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Gold Really Boring? (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Gold Really Boring? (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Stocks That Really, Really Need the Defense Bill to Pass
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Gold Really Boring? (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows

Prothena (PRTA) Stock Forecast, Price & News

$47.60
+0.30 (+0.63%)
(As of 09/26/2023 ET)
Compare
Today's Range
$45.22
$47.93
50-Day Range
$47.30
$69.05
52-Week Range
$28.99
$79.65
Volume
576,001 shs
Average Volume
394,026 shs
Market Capitalization
$2.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.56

Prothena MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
83.9% Upside
$87.56 Price Target
Short Interest
Bearish
7.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.19mentions of Prothena in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$4.14 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($4.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

721st out of 963 stocks

Pharmaceutical Preparations Industry

329th out of 446 stocks


PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Price History

PRTA Stock News Headlines

Prothena (NASDAQ:PRTA) Upgraded to "Hold" at StockNews.com
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Prothena (NASDAQ:PRTA) Downgraded by StockNews.com to Sell
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
RBC Capital Keeps Their Hold Rating on Prothena (PRTA)
Prothena Corp's Earnings Outlook
Prothena Plc (NASDAQ: PRTA)
Expert Ratings for Prothena Corp
Jefferies Keeps Their Buy Rating on Prothena (PRTA)
Prothena (PRTA) Receives a Buy from Bank of America Securities
Prothena (PRTA) Receives a Buy from JMP Securities
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$87.56
High Stock Price Forecast
$129.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+83.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-116,950,000.00
Net Margins
-244.45%
Pretax Margin
-266.80%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$12.86 per share

Miscellaneous

Free Float
38,438,000
Market Cap
$2.55 billion
Optionable
Optionable
Beta
0.39
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Gene G. Kinney Ph.D.Dr. Gene G. Kinney Ph.D. (Age 54)
    Pres, CEO & Director
    Comp: $1.03M
  • Mr. Tran B. Nguyen M.B.A.Mr. Tran B. Nguyen M.B.A. (Age 49)
    CFO & Chief Strategy Officer
    Comp: $762.86k
  • Mr. Brandon S. Smith (Age 48)
    Chief Operating Officer
    Comp: $756.41k
  • Ms. Carol D. KarpMs. Carol D. Karp (Age 70)
    Chief Regulatory Officer
    Comp: $697.51k
  • Dr. Hideki Garren M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $809.59k
  • Ms. Karin L. Walker CPAMs. Karin L. Walker CPA (Age 60)
    CPA, Chief Accounting Officer & Controller
  • Dr. Wagner M. ZagoDr. Wagner M. Zago (Age 50)
    Chief Scientific Officer
  • Ms. Jennifer Zibuda
    Director of Investor Relations & Communication
  • Mr. Michael J. MalecekMr. Michael J. Malecek (Age 57)
    Chief Legal Officer & Company Sec.













PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2023?

10 analysts have issued 12 month target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $129.00. On average, they predict the company's stock price to reach $87.56 in the next year. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA shares have decreased by 21.0% and is now trading at $47.60.
View the best growth stocks for 2023 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its earnings results on Thursday, August, 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.11. The biotechnology company earned $4.02 million during the quarter, compared to the consensus estimate of $5.09 million. Prothena had a negative trailing twelve-month return on equity of 25.43% and a negative net margin of 244.45%. The company's quarterly revenue was up 206.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.75%), State Street Corp (3.50%), Dimensional Fund Advisors LP (2.15%), Geode Capital Management LLC (1.57%), Bank of New York Mellon Corp (0.97%) and Nuveen Asset Management LLC (0.85%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $47.60.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $2.55 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How many employees does Prothena have?

The company employs 127 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -